Quality Project to Evaluate and Validate the FAST-O Rating Scale

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00913731
First received: June 2, 2009
Last updated: October 28, 2009
Last verified: October 2009
  Purpose

The purpose of this project is to test the reliability of the FAST-O Rating Scale in patients at acute wards or psychiatric intensive care units.


Condition
Acute Psychotic Symptoms

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Quality Project to Evaluate and Validate the FAST-O Rating Scale (Fast ASessment in Acute Treatment of Psychosis-Observation)

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Reliability test of the FAST-O rating scale based on observational symptom ratings of patients with acute psychotic diseases [ Time Frame: Each patients symtoms will be rated on 2 occasions, by 2-3 raters, each. First is made within 24 hrs of admission to acute psychiatric care, secondis made 14 +/- 2 days after admittance, or earlier if the patient is discharged. ] [ Designated as safety issue: No ]

Enrollment: 111
Study Start Date: May 2009
Study Completion Date: October 2009
Groups/Cohorts
psychotic patients
psychotic patients, acute ward, symptom rating scale.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with acute psychotic symptoms attending the acute ward or psychiatric intensive care unit

Criteria

Inclusion Criteria:

  • Patients with acute psychotic symptoms attending the acute ward or psychiatric intensive care unit

Exclusion Criteria:

  • Not applicable
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00913731

Locations
Sweden
Research Site
Helsingborg, Sweden
Research Site
Kristianstad, Sweden
Research Site
Lund, Sweden
Research Site
Malmo, Sweden
Research Site
Ystad, Sweden
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Eva Dencker Vansvik Medical Department
Principal Investigator: Eva Lindström Rättspsyk, UMAS, Malmö
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00913731     History of Changes
Other Study ID Numbers: NIS-NSE-DUM-2008/1
Study First Received: June 2, 2009
Last Updated: October 28, 2009
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by AstraZeneca:
Psychotic symptom assessments
Observational assessments of patients with acute psychotic symptoms

Additional relevant MeSH terms:
Mental Disorders
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on July 31, 2014